Our research and development efforts have been primarily focused on building a portfolio of proprietary drug candidates based on allosteric modulation, which we believe has broad applicability across a wide range of biological targets and therapeutic areas. Our primary focus has been on G-protein coupled receptors, or GPCR, targets implicated in neurological diseases, where we believe there is a clear medical need for new therapeutic approaches. Based on this, we have developed a pipeline of proprietary clinical and preclinical stage drug candidates. We or our partners are developing these clinical and preclinical stage proprietary drug candidates for diseases for which there are no approved therapies or where improved therapies are needed. These include epilepsy, post-stroke sensorimotor recovery, traumatic brain injury recovery, Parkinson’s disease levo-dopa induced dikynesia, or PD-LID, substance use disorder, or SUD, and chronic cough.. Some of these indications are classified as rare diseases that may allow for orphan drug designation by regulatory agencies in major commercial markets, such as the United States, Europe and Japan. Orphan drug designation may entitle the recipient to benefits, in the jurisdiction granting the designation, such as market exclusivity following approval and assistance in clinical trial design, a reduction in user fees or tax credits related to development expenses.